BioGaia entered into an agreement for BioGaia's probiotic drops with the Swiss pharmaceutical company Ferring Pharmaceuticals in March 2006 covering Spain, Portugal, Hungary and Czech republic. The agreement also gave Ferring optional rights to several other countries.
Ferring and BioGaia have agreed to extend the exclusive license to sell BioGaia's probiotic drops to include Canada and several Middle East countries.
The regulatory process is now initiated in all countries covered by the agreement and two countries, Canada and Portugal, will launch the product during the autumn.
BioGaia's probiotics drops are today being sold in 7 countries and the Company has agreements for 11 additional countries, where launches are being planned. The product, specially adapted to infants, improves gastrointestinal function and has been shown to have significant clinical effects on colic.
BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (Reuteri), which has health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the O list of the Stockholm Stock Exchange.
BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health effects. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri (ReuteriÒ), which has probiotic or health-enhancing effects. The Parent Company BioGaia AB's class B share is quoted on the O list of the Stockholm Stock Exchange.